PUBLIC COMPANY
save$NUVLNuvalent, Inc.
$NUVL123.960.00%Cambridge, MA, USupdated 3mo ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2pre_registration
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
- phase3Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- —Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors
- —Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors
- phase2A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- phase2A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 49m ago
Found something off?
comments(0)
5-min edit window · permanent after that